91 related articles for article (PubMed ID: 17474437)
1. [Overcoming imatinib resistance].
Ashihara E; Maekawa T
Nihon Rinsho; 2007 Jan; 65 Suppl 1():399-403. PubMed ID: 17474437
[No Abstract] [Full Text] [Related]
2. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Deininger MW; Druker BJ
Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
[TBL] [Abstract][Full Text] [Related]
3. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
Singh T; Casson C
Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
[TBL] [Abstract][Full Text] [Related]
4. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
5. Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: before or after imatinib?
Tefferi A
Cancer; 2011 Jan; 117(2):234-7. PubMed ID: 21210471
[No Abstract] [Full Text] [Related]
6. Strategies for the treatment of imatinib-resistant chronic myeloid leukemia.
Hui CH; Hughes TP
Clin Adv Hematol Oncol; 2003 Sep; 1(9):538-45, 559. PubMed ID: 16258446
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of imatinib mesylate.
Levêque D; Maloisel F
In Vivo; 2005; 19(1):77-84. PubMed ID: 15796158
[TBL] [Abstract][Full Text] [Related]
8. Imatinib and pregnancy.
Ali R; Ozkalemkas F; Ozcelik T; Ozkocaman V; Ozkan A
J Clin Oncol; 2006 Aug; 24(23):3812-3; author reply 3813. PubMed ID: 16896012
[No Abstract] [Full Text] [Related]
9. Update on the use of imatinib mesylate.
Sawyers CL
Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
[No Abstract] [Full Text] [Related]
10. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
11. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Cashen A; DiPersio JF; Khoury H
J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
[No Abstract] [Full Text] [Related]
12. Cutaneous reactions to STI571.
Brouard M; Saurat JH
N Engl J Med; 2001 Aug; 345(8):618-9. PubMed ID: 11529225
[No Abstract] [Full Text] [Related]
13. [Imatinib mesylate: a major breakthrough in the treatment of chronic myelogenous leukemia].
Turhan A
Med Sci (Paris); 2003; 19(6-7):667-8. PubMed ID: 12942435
[No Abstract] [Full Text] [Related]
14. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Marin D; Kaeda JS; Andreasson C; Saunders SM; Bua M; Olavarria E; Goldman JM; Apperley JF
Cancer; 2005 May; 103(9):1850-5. PubMed ID: 15786422
[TBL] [Abstract][Full Text] [Related]
15. [New target-aimed molecular cancer treatment of chronic myeloid leukemia and gastrointestinal stromal tumor].
Dufva IH; Birgens H
Ugeskr Laeger; 2001 Aug; 163(35):4759-60. PubMed ID: 11572056
[No Abstract] [Full Text] [Related]
16. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
Lazarevic V; Golovleva I; Nygren I; Wahlin A
Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
[No Abstract] [Full Text] [Related]
17. [Treatment strategies for chronic myeloid leukemia].
Jinnai I
Rinsho Ketsueki; 2005 Jan; 46(1):1-6. PubMed ID: 16708910
[No Abstract] [Full Text] [Related]
18. Discontinuation of imatinib may be possible in chronic myelogenous leukemia.
Barton MK
CA Cancer J Clin; 2011; 61(2):65-6. PubMed ID: 21372196
[No Abstract] [Full Text] [Related]
19. Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.
Breccia M; Stagno F; Vigneri P; Latagliata R; Cannella L; Del Fabro V; Di Raimondo F; Alimena G
Am J Hematol; 2010 May; 85(5):375-7. PubMed ID: 20306543
[No Abstract] [Full Text] [Related]
20. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
